Efficacy and safety of the selective α1a-adrenoceptor blocker silodosin for severe lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, single-open-label, multicenter study in Korea

Title
Efficacy and safety of the selective α1a-adrenoceptor blocker silodosin for severe lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, single-open-label, multicenter study in Korea
Author(s)
문기학송필현Dae Yul Yang[Dae Yul Yang]Nam Cheol Park[Nam Cheol Park]Soo Woong Kim[Soo Woong Kim]Sung Won Lee[Sung Won Lee]Sae Woong Kim[Sae Woong Kim]Du Geon Moon[Du Geon Moon]Jong Kwan Park[Jong Kwan Park]Tai Young Ahn[Tai Young Ahn]Kwangsung Park[Kwangsung Park]
Keywords
silodosin; adult; aged; article; clinical trial; disease association; dizziness; drug efficacy; drug safety; drug withdrawal; ejaculation disorder; headache; human; intention to treat analysis; International Prostate Symptom Score; Korea; lower urinary tract symptom; major clinical study; male; middle aged; multicenter study; open study; orthostatic hypotension; postvoid residual urine volume; prospective study; prostate hypertrophy; quality of life; thorax pain; transrectal ultrasonography; treatment outcome; urine flow rate; urine volume; very elderly
Issue Date
201405
Citation
Korean Journal of Urology, v.55, no.5, pp.335 - 340
Abstract
Purpose To evaluate the efficacy and safety of silodosin 8 mg once daily in a 12-week treatment of subjects with severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Materials and Methods: A total of 100 subjects from 10 urology centers in Korea were included in this study. The inclusion criteria were as follows: age ��50 years, International Prostate Symptom Score (IPSS) �� 20, quality of life (QoL) score ��3, urine volume ��120 mL and maximal urinary flow rate (Qmax) <15 mL/s, and postvoid residual volume (PVR) <100 mL. We assessed the improvement of LUTS with change in IPSS, QoL score, Qmax, PVR, and adverse events at baseline and 4 and 12 weeks after treatment with silodosin 8 mg once daily. Results: The IPSS values were 23.27��3.34, 15.89��6.26, and 13.80��6.31 at baseline, 4, and 12 weeks, respectively, with significant improvements (p<0.0001, p=0.0214, respectively). QoL scores were 4.44��0.85, 3.38��1.20, and 3.04��1.20 at baseline, 4, and 12 weeks, respectively, and the differences were statistically significant (p<0.0001). There was a significant difference in Qmax between baseline and 12 weeks (p<0.0001) but not in PVR (p=0.9404) during the clinical trial. The most frequent adverse event in this study was ejaculation failure with 13 cases. However, no subject dropped out because of ejaculation failure, and in 12 of the 13 cases it was fully resolved without further treatment. Conclusions: Silodosin 8 mg once daily may be effective and safe in Korean patients with severe LUTS associated with BPH. ? The Korean Urological Association, 2014.
URI
http://hdl.handle.net/YU.REPOSITORY/32146http://dx.doi.org/10.4111/kju.2014.55.5.335
ISSN
2005-6737
Appears in Collections:
의과대학 > 비뇨기과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE